Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Antifungal Drugs Market 

5.1. COVID-19 Landscape: Antifungal Drugs Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Antifungal Drugs Market, By Drug Class

8.1. Antifungal Drugs Market, by Drug Class, 2023-2032

8.1.1 Echinocandins

8.1.1.1. Market Revenue and Forecast (2020-2032)

8.1.2. Azoles

8.1.2.1. Market Revenue and Forecast (2020-2032)

8.1.3. Allylamines

8.1.3.1. Market Revenue and Forecast (2020-2032)

8.1.4. Polyenes

8.1.4.1. Market Revenue and Forecast (2020-2032)

8.1.5. Others

8.1.5.1. Market Revenue and Forecast (2020-2032)

Chapter 9. Global Antifungal Drugs Market, By Indication

9.1. Antifungal Drugs Market, by Indication, 2023-2032

9.1.1. Aspergillosis          

9.1.1.1. Market Revenue and Forecast (2020-2032)

9.1.2. Dermatophytosis

9.1.2.1. Market Revenue and Forecast (2020-2032)

9.1.3. Candidiasis

9.1.3.1. Market Revenue and Forecast (2020-2032)

9.1.4. Others

9.1.4.1. Market Revenue and Forecast (2020-2032)

Chapter 10. Global Antifungal Drugs Market, By Infection Type 

10.1. Antifungal Drugs Market, by Infection Type, 2023-2032

10.1.1. Systemic Antifungal Infections

10.1.1.1. Market Revenue and Forecast (2020-2032)

10.1.2. Superficial Antifungal Infections

10.1.2.1. Market Revenue and Forecast (2020-2032)

Chapter 11. Global Antifungal Drugs Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.1.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.1.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.6.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.2.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.2.7.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.6.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.3.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.3.7.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.6.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.6.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.4.7.2. Market Revenue and Forecast, by Indication (2020-2032)

11.4.7.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.4.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.4.3. Market Revenue and Forecast, by Infection Type (2020-2032)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Drug Class (2020-2032)

11.5.5.2. Market Revenue and Forecast, by Indication (2020-2032)

11.5.5.3. Market Revenue and Forecast, by Infection Type (2020-2032)

Chapter 12. Company Profiles

12.1. Pfizer, Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Novartis AG

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Sanofi

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. GlaxoSmithKline plc

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Bayer AG

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Glenmark

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Abbott

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. AstellasPharma, Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Enzon Pharmaceuticals, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms